(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mossad unveils network of Hamas terror infrastructure across Europe - 2Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- 3Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- 4Dick Van Dyke shares his secrets to longevity as he turns 100
- 5Lula’s former human rights minister formally accused of sexual misconduct
- A Time of Careful Eating: Individual Tests in Nourishment
- People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- Investigating Remarkable Espresso Flavors: Upgrade Your Day to day Blend
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- Manual for Financial plan Agreeable PC
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Seven deaths possibly linked to malfunctioning glucose monitors
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
